2018年毕业于四川大学华西药学院药学专业，获理学学士学位。同年保送至四川大学华西药学院药剂学专业，并于2023年毕业，获理学博士学位。然后在华西基础医学与法医学院任助理研究员，专职博士后。目前主要的研究方向为肿瘤转移的发生机制及调控。参与国家自然科学基金面上项目和四川省科技厅重点项目的研究。先后发表SCI论文16篇。

从事生物分子基础实验的课程教学工作。

1. Rong Guo, Miao Deng, Jiaxin Li, Xuan He, Penghui He, Houqin Liu, Yunxia Ye, Ziyi Mo, Xuan He, Man Li, Qin He. Depriving tumor cells of ways to metastasize: Ferroptosis nanotherapy blocks both hematogenous metastasis and lymphatic metastasis[J]. Nano Letters, 2023, 23(8):3401-3411.

2. Rong Guo, Miao Deng, Mengmeng Li, Jiaxin Li, Penghui He, Man Li, Zhirong Zhang, Qin He. Fucoidan-functionalized activated platelets-hitchhiking micelles simultaneously track tumor cells and remodel the immunosuppressive microenvironment for efficient metastatic cancer treatment[J]. Acta Pharmaceutica Sinica B, 2022, 12(1):467-482.

3. Rong Guo*, Yang Long*, Zhengze Lu, Miao Deng, Penghui He, Man Li, Qin He. Enhanced stability and efficacy of GEM-TOS prodrug by co-assembly with antimetastatic shell LMWH-TOS[J]. Acta Pharmaceutica Sinica B, 2020, 10(10):1977-1988.

4. Miao Deng, Rong Guo, Shuya Zang, Jingdong Rao, Mengmeng Li, Xian Tang, Chunyu Xia, Man Li, Zhirong Zhang, Qin He. pH-triggered copper-free click reaction mediated micelle aggregation for enhanced tumor retention and elevated immuno-chemotherapy against melanoma[J]. ACS Applied Materials Interfaces, 2021, 13(15):18033-18046.

5. Mengmeng Li, Rong Guo, Jiaojie Wei, Miao Deng, Jiaxin Li, Yuan Tao, Man Li, Qin He. Polydopamine-based nanoplatform for photothermal ablation with long-term immune activation against melanoma and its recurrence[J]. Acta Biomateralia, 2021, 136:546-557.

6. Jiaxin Li, Yang Long, Rong Guo, Kebai Ren, Zhengze Lu, Man Li, Xuhui Wang, Jiaxin Li, Yashi Wang, Zhirong Zhang, Qin He. Shield and sword nano-soldiers ameliorate rheumatoid arthritis by multi-stage manipulation of neutrophils[J]. Journal of Controlled Release, 2021, 335:38-48.

7. Jiaojie Wei, Yang Long, Rong Guo, Xinlei Liu, Xian Tang, Jingdong Rao, Sheng Yin, Zhirong Zhang, Man Li, Qin He. Multifunctional polymeric micelle-based chemo-immunotherapy with immune checkpoint blockade for efficient treatment of orthotopic and metastatic breast cancer[J]. Acta Pharmaceutica Sinica B, 2019, 9(4):819-831.